A New Broad-Spectrum H5N1 Vaccine Could Protect Livestock and the People Who Work With Them

When highly pathogenic avian influenza was first confirmed in dairy cattle in March 2024, it caught the scientific community off guard. Influenza jumping to a new species, particularly one with as much human contact and economic significance as dairy cattle, was not in the expected playbook. For Eric Weaver, director of the Nebraska Center for Virology and professor at the University of Nebraska-Lincoln, it was a signal that the response needed to start immediately.

His team's answer is a broad-spectrum H5N1 vaccine built around 28 years of viral evolution, designed to hold up against current and future strains. It has been tested in mice, ferrets, pigs, and dairy cattle. Under lethal challenge conditions in mice, it showed 100% efficacy. The team's goal is a market-ready product within the next few years, priced affordably enough to make economic sense for producers already operating on tight margins.

The Science Behind the Breadth

Most vaccines target a specific strain or a narrow window of viral variation. Weaver's team took a different approach, tracing H5N1 back to its ancestral strain and building a vaccine that incorporates the full range of evolutionary variants produced over nearly three decades. The logic is that a vaccine anchored at the root of the evolutionary tree should generate protective immune responses not just against known strains, but against variants that emerge outside that documented history.

The data from animal studies supports that premise. The team saw protective immune responses across the full 28-year evolutionary range, which is the foundation for their confidence that the vaccine could hold up against future variants.

Why Dairy Cattle Matter Beyond the Farm

H5N1 in dairy cattle carries a relatively low mortality rate. The economic damage comes primarily from milk production loss, which hits an industry with little margin to absorb it. But Weaver is clear that the stakes extend well beyond farm economics.

The longer the virus circulates in dairy cattle, the more opportunity it has to mutate toward forms with higher transmission efficiency. Anything that transmits efficiently from animal to animal in a mammalian species is, by definition, a closer evolutionary step toward human-to-human transmission. Weaver frames the cattle vaccination question as inseparable from the pandemic preparedness question, and the science backs that framing.

This vaccine started as a human bird flu vaccine. The decision to adapt it for livestock reflects a recognition that controlling circulation in animal reservoirs is one of the most effective upstream interventions available in pandemic prevention, well before a human-adapted strain emerges.

Delivery and Accessibility

The team is currently evaluating two delivery methods: intramuscular injection and intranasal administration. Original studies tested both simultaneously. The next phase will assess whether intranasal delivery alone maintains the same level of protection, which would have meaningful practical implications. A needle-free administration route reduces biosafety burden for farm workers and simplifies the vaccination process at scale.

On cost, Weaver is direct. The manufacturing approach and dosing requirements already put the vaccine in an affordable range. Scaling up for commercial production would not fundamentally change that, making producer adoption a realistic outcome rather than an aspirational one.

The Longer Goal

Weaver's team is working toward an all-in-one vaccine that could protect multiple livestock species. Beef cattle have not yet experienced the H5N1 outbreaks that dairy herds have, but the potential consequences of that changing, either through increased transmission efficiency in cattle populations or a mutation toward sustained human-to-human spread, are difficult to fully quantify and straightforward to take seriously.

For veterinary professionals advising dairy operations or engaged in food animal practice, this research represents the kind of upstream investment the profession has been asking for since H5N1 first appeared in cattle. A broad-spectrum, affordable, potentially needle-free vaccine that addresses both production losses and pandemic risk is not a small thing. It's exactly what the next phase of HPAI response needs to look like.

TAGS: HPAI, H5N1, avian influenza, dairy cattle, vaccine development, One Health, food animal, pandemic prevention, livestock, University of Nebraska, research